|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||10.60 - 11.45|
|52 Week Range||3.88 - 11.45|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
"Thirty seconds for the market to open," a Toronto Stock Exchange representative said as the crowd started to clap, cheer and celebrate. It was the anniversary of the Evolve Marijuana ETF (TSX:SEED)(OTC:EVVLF) and they were celebrating being the best-performing equity ETF on the TSX in the last year.
NEW YORK , April 17, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the first quarter 2019 performance ...
Horizons is the company behind the Horizons Marijuana Life Sciences Index ETF (TSX: HMMJ)(OTC: HMLSF), which is one of the world's largest cannabis ETFs. “HMUS will be the first ETF in the world that is solely focused on providing exposure to companies with significant business activities in, or significant exposure to, the United States marijuana or hemp industries,” according to a statement.
Marijuana stocks have become much more accepted by mainstream investors in the past few years. However, just because investing in cannabis is getting more common doesn't mean it's not dangerous territory for investors.A parade of marijuana stocks has listed on major U.S. exchanges since the beginning of 2018. In addition, a growing number of Wall Street analysts are now covering marijuana stocks. Cannabis investors are no longer automatically smirked at. Unfortunately, there are still plenty of dangers lurking in the cannabis market. The Dangers Of OTC StocksMarijuana stocks like Canopy Growth Corp (NYSE: CGC), Tilray (NASDAQ: TLRY) and Aurora Cannabis (NYSE: ACB) have gained legitimacy in the past year by transitioning to the NYSE and Nasdaq exchanges.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 AI Stocks to Watch with Strong Long-Term Narratives At the same time, U.S. multi-state cannabis operators like Curaleaf Holdings (OTC: CURL), Medmen Enterprises (OTC: MMNFF) and Green Thumb Industries (OTC: GTBIF) are currently relegated to trading on the OTC market. Since these companies are technically running U.S. businesses that contravene federal laws, they will likely stay on the OTC market for the time being.OTC stocks have a somewhat poor reputation among average investors. Many OTC stocks trade for under $1 per share, and it's common for OTC stocks to provide little financial information to investors. The information these companies do provide is often unreliable.As a result, it can be difficult for investors to get a clear picture of what's going on at companies with OTC stocks. Essentially, all companies need to do to list on the OTC is fill out a request form.Most cannabis stocks are far from the typical, sketchy, OTC-listed stock. However, that doesn't mean all the dangers mentioned above don't still apply to them. Medmen's Fake NewsSince information about OTC-listed stocks can be difficult to obtain, greedy traders and greedy companies can take advantage of the situation. Companies listed on the OTC markets are notorious for carrying out "pump-and-dump" schemes. Those schemes involve companies or third parties flooding message boards and social media platforms with fake news about a stock to drive its price higher. These companies or third parties will then cash out at the peak, and other buyers of the stock will get burned.Pump-and-dump schemes are technically illegal. But so is driving over the speed limit, and plenty of people still get away with it. And if you think these types of stock-promotion schemes aren't used to pump and dump reputable cannabis stocks, you're wrong.Seven analysts are currently covering Medmen (OTC: MMNFF), and six of the seven analysts recommend that investors buy MMNFF stock. Yet just last month, Medmen admitted to using an agreement with a company called Winning Media to promote MMNFF stock. In a press release, Medmen said it "disclaims any potentially exaggerated or misleading statements contained in the materials" distributed online by Winning Media. But at that point, the damage to the owners of MMNFF stock may have already been done.Medmen will likely be particularly careful in the future about the types of public relations deals that it makes. However, given how thinly-traded the OTC market is, stock promoters don't need companies' permission to promote stocks. The promoters can simply take a position in a stock, spread fake news online and cash out. The company may be none the wiser. Avoiding Pump-and-Dump Cannabis StocksFortunately for cannabis investors, there are ways to avoid being misled by promoters. According to Todd Fromer, the managing partner of KCSA Strategic Communications, common sense can go a long way for cannabis-stock investors. Fromer says investors can watch for certain red flags when reading about marijuana stocks online.First, only trust reputable news sources. A good rule of thumb is to consider whether or not you've heard of the website before. For example, a news article on Bloomberg or CNBC is fine. An article on GetRichQuickWithPennyStocks.com may not be.Second, look for disclosures indicating the article is an advertisement. Finally, use common sense to identify stories that are too good to be true. Actual journalists will almost never make claims like "1000% upside" or "guaranteed profits.""As the cannabis sector continues to gain momentum it's critical that both investors and company management remain vigilant," Fromer recently wrote.Marijuana stocks have taken major strides in recent quarters towards leaving their shady past behind. Unfortunately, some U.S. cannabis companies still have a long way to go. In the meantime, just because cannabis stocks are getting much more mainstream media coverage doesn't mean investors can let their guard down. Don't believe everything you read about marijuana stocks.As of this writing, Wayne Duggan did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Best Dividend Stocks to Buy for Every Investor * 7 Catalysts That Will Send Marijuana Stocks Soaring in 2019 * 8 Risky Stocks to Watch as Earnings Season Kicks Off Compare Brokers The post Don't Believe Everything You Read About Marijuana Stocks appeared first on InvestorPlace.
Is There More Upside to Curaleaf Holdings’ Stock Price?(Continued from Prior Part)Analysts’ recommendationsAmong the six analysts that follow Curaleaf Holdings (CURA) (CURLF), three recommended a “strong buy,” while three recommended a
Is There More Upside to Curaleaf Holdings’ Stock Price?Stock performance Curaleaf Holdings (CURA) (CURLF) has started 2019 on a stronger note. As of April 9, the company’s stock price has increased 83.0% since the beginning of the year. In
Planet 13 and Wayland Group Posted Strong Performance Last Week(Continued from Prior Part)Stock performance Cannabis stocks were mixed last week. Of the seven companies considered for our analysis in this article, three have given positive returns,
Planet 13’s Superstore Earned Revenues of $5.5 Million in MarchRevenue growth Planet 13 Holdings (PLNHF) (PLTH) announced today that its Las Vegas Cannabis Entertainment Complex, also called the Superstore, posted revenue of $5.5 million in March.
The positive response to China trade negotiation headlines is becoming too routine and is starting to generate more of a "sell the news" response. While there is still optimism about positive progress, the headlines have been non-specific and market players are more skeptical of the quick moves on the news.
The indices aren't doing much Tuesday and breadth is rather poor -- about 3,000 gainers to 4,250 decliners. This is healthy action, though. After the move Monday some time is needed for short-term players to take profits and for shares to move into the hands of stronger players with more confidence about further upside.
HENDERSON, NV / ACCESSWIRE / April 1, 2019 / According to the Cannabis Energy Report released by New Frontier Data last October, the production of legal cannabis is projected to consume 162 % more energy ...
WAKEFIELD, Mass., April 1, 2019 /PRNewswire/ -- Curaleaf Holdings, Inc. (CSE: CURA / OTCQX: CURLF), a leading vertically integrated cannabis operator in the United States, today announced that it completed the acquisition of EC Investment Partners, LLC ("Eureka"). "The acquisition of Eureka cements our foundation in California and positions us well in the largest cannabis consumption market in the U.S.," said Joseph Lusardi, CEO of Curaleaf. Curaleaf has the largest footprint of single-branded retail stores in the U.S. and is executing on its strategy of building a national brand in highly populated states.
When I tell people that marijuana stocks may be one of the best investment opportunities of their lifetimes, I think their minds usually go to the more dramatic story of "legal weed" -- like the "cannabis cafes" popping up everywhere from West Hollywood to Alaska.However, I've long thought that its non-psychoactive cousin, cannabidiol (CBD), could be the real growth opportunity.But don't take my word for it. CVS Health Corp (NYSE:CVS) and Walgreens Boots Alliance (NASDAQ: WBA) apparently see the same thing.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIn the last week, both CVS and Walgreens have announced that they will start selling CBD in several different states. (Specifically, the topical creams, etc., for pain relief.) We're talking about huge pharmacy brands; CVS stores in particular are ubiquitous in major U.S. cities -- and now that it's operating Target (NYSE:TGT) pharmacies, that goes for the suburbs, too.So for CBD companies like the one we'll look at in a minute, access to these massive distribution networks is a big deal. According to the Brightfield Group, we can expect hemp-derived CBD sales at chained retailers to go from zero in 2018 to $13.9 billion in 2022. That'll be about two-thirds of an overall $22 billion market. * 8 Genomic Testing Stocks That Can Ease the Sting of Theranos But maybe an even bigger deal is that CVS was the first "big box" retailer to jump on the bandwagon.CVS is increasingly conservative with its offerings when it comes to pain meds. Most folks can't get more than seven days' worth of opioids. And even each day's dose is limited, depending on the strength of what's prescribed.So, the fact that CVS is selling CBD really underscores what I've been saying all along:CBD is one of the most beneficial compounds you can get, without the nasty side effects of drugs. It's now a part of my normal health and wellness activities -- I take it every night before I go to bed. Over the years, I have turned friends, family, and colleagues on to the benefits of CBD and seen positive changes in their lives as well.I know people who suffer from chronic pain. And, of course, the standard treatment is opioids. The biggest reason for that is simple -- the power of global pharmaceutical conglomerates. Unfortunately, we now see the tragic consequences every day.We are now losing 130 people a day to opioids in the United States, according to the CDC. And many turn from pills to heroin, causing those overdose rates to skyrocket.How many people overdose on non-synthetic CBD? Zero. There aren't even any major side effects.With the recently passed 2018 U.S. Farm Bill that legalized industrial hemp, I expect we'll start to see the research and education we need to have CBD largely replace opioids across the country.The impact of that would be enormous. In 2016, the U.S. opioid market was valued at $23 billion. I expect a large amount of that to shift to alternatives in the next few years, most notably CBD, so we're talking about billions of dollars.And it's also interesting to note that CVS is far and away the leading pharmacy when it comes to prescription revenues. It brings in almost as much as its next two competitors -- Walgreens and Cigna (NYSE:CI)/Express Scripts -- combined.So, CVS could be an especially key player in the growth story of medical marijuana, in addition to the Curaleaf (OTCMKTS: CURLF) branded topical CBD the company will now be selling.When major retailers get involved in formerly "niche" products, the sky is usually the limit. Impact on Cannabis StocksFrom an investment perspective, the sales projections -- and the opportunity to steal market share from Big Pharma opioids -- make marijuana stocks a compelling growth story. And, specifically, CBD stocks.Curaleaf took off on the CVS partnership news, by as much as 49%.Charlotte's Web Holdings (OTCMKTS:CWBHF) did well, too… and it's a pure play on hemp-CBD. It's also my pick for InvestorPlace's Best Stocks for 2019 contest.In researching CBD stocks when few others were, Charlotte's Web stood out as the clear leader. It's set to grow more than 100% annually over the next five years, as it's uniquely qualified to benefit from the trends I just laid out.The company gets its name from a little girl named Charlotte who was suffering almost constant grand mal seizures, but saw them largely disappear after trying CBD oil. (I've covered Charlotte's story before, and you really ought to check it out. It's truly amazing.)These days, Charlotte's Web is a $1.8 billion company by market cap, and its quarterly revenue trends are powerful:As I mentioned when I named Charlotte's Web as my Best Stock pick, the company is really ramping up its production… so in the future, when CVS or one of its peers is looking for CBD, they'll come calling on Charlotte's Web.Wall Street is starting to catch on, driving the stock more than 68% higher since I recommended it in Investment Opportunities just six months ago. I'm glad to have spotted it early.And throughout my career, I've found that investing in the early innings is key.If you'd known how to play Visa (NYSE:V) a few years ago, as my readers did, you'd have seen it go from $17 to $150.Same thing with Ulta Beauty (NASDAQ:ULTA), which went from $60 to over $300 for us.Now, marijuana and CBD stocks are one of the key areas I'm turning to for early-stage profits.I certainly don't just buy any old IPO. I want to see that the company can make money first. Plus, it's crucial to get the timing right.That's what I designed my Cannabis Cash Calendar system to do for marijuana IPOs. And our first play is seeing 120% gains in less than four months!On April 4th -- next Thursday -- I am planning to release my next Cannabis Cash Calendar recommendation. You can get exclusive access to it as soon as it's released to my Investment Opportunities readers. Click here to learn more about this opportunity and how to get on the list to be notified.Maybe you don't know much more about marijuana stocks than what I've said here. That's fine. Even if you've never even bought a stock before, you'll want to check this out. I'd say take a small stake…and you could potentially see that multiply over the next 12 months. Click here to learn more about this incredible story.Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Best Bond Funds to Buy for a Shift in Interest Rates * 10 Tech Stocks With Key Products That Face an Uncertain Future * 7 SaaS Stocks to Buy for Long-Term Gains Compare Brokers The post Marijuana Stocks Go Mainstream As CBD Jumps to CVS and Walgreens appeared first on InvestorPlace.
Of the big themes in the cannabis sector for 2019 will be a focus shift to the American companies. The market spent most of 2018 obsessed with the large Canadian players that listed on major U.S. stock exchanges while some large American companies are still under the radar such as Curaleaf Holdings (CURLF).Multi-State PlayDue to the fragmented nature of the U.S. cannabis market with legality based on state levels and illegal on a federal level, the companies involved haven’t garnered the press of the Canadian players with global plans and large partnerships. The interesting part is that a company like Curaleaf has an expanded presence in 12 states providing a larger market than the domestic opportunity in Canada.At the end of 2018, Curaleaf operated 36 dispensaries, 12 cultivation sites and 10 processing sites. The company has already added another 7 dispensaries and a processing site this year. As additional states legalize cannabis, Curaleaf is positioned to grab an even larger market without having to expand to international locations where they’ll have to compete with local providers and exporters from other countries.In addition, Curaleaf has agreed to acquire Acres Cannabis for a massive 19,000 sq. ft. dispensary in Las Vegas along with cultivation plans of 100,000 pounds of dry flower per year. The $70 million deal seems reasonable in comparison to some of the large Canadian deals, though financial forecasts of Acres weren’t provided.Large Revenue Base with CatalystsFor the December quarter, Curaleaf reported revenues of $32 million for an annualized rate of $128 million. The number isn’t massive for a $4 billion market cap, but a substantial amount above the less than $5 million produced by Cronos that got a major deal from Altria. Before the recent selloff, Cronos was worth nearly double that of Curaleaf at a $7 billion market valuation.The company generated revenues of $77.1 million for 2018 with a forecast to top managed revenue of $400 million in 2019. Maybe more importantly is the goal of generating $100 million in free cash flow for the year.One still ends up with a stock that isn’t exactly cheap trading at about 10x those revenue estimates. Just assuming 50% revenue growth in 2020 and the stock is reasonably trading at about 6.7x a basic revenue estimate of $600 million in 2020 with plenty upside.Several catalysts exist for the stock in 2019. The potential exists for Curaleaf to eventually uplist from the OTC market assuming the federal government finally approves cannabis operations. In addition, the CBD deal with CVS Health (CVS) for 800 stores has the ability to eventually expand to the majority of their 10,000 pharmacy locations. CVS has started selling CBD creams, sprays and lotions in eights states so one can easily envision the expansion possibilities with this deal alone.TakeawayThe key investor takeaway is that Curaleaf, along with other American cannabis stocks, have been generally ignored due to the inability to list on major U.S. exchanges. The stock isn’t exceptionally cheap, but Curaleaf is on a path to substantial revenue growth and scale while trading at a fraction of the market values of the large Canadian cannabis stocks that have valuations in the $10 billion range.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. More recent articles from Smarter Analyst: * MKM Continues to Recommend Micron (MU) Stock; Here's Why * Advanced Micro Devices (AMD) Stock Is Back in a Big Way * Cannabis Stock Canopy Growth (CGC) Could Race Above $60, but Caution Is Warranted * Jeff Bezos Is Leading Amazon (AMZN) in the Right Direction
WASHINGTON, March 28, 2019 /PRNewswire/ -- Curaleaf Holdings, Inc. (CURA.CN) (CURLF) ("Curaleaf" or the "Company"), a leading vertically integrated cannabis operator in the United States, and the Veterans Cannabis Project (VCP), an organization that advocates for unrestricted and supported access of medical cannabis for veterans, today announced an initiative that seeks to raise awareness and marks an important milestone to make legal cannabis more accessible for veterans. A custom designed "Veterans Cannabis Project" pre-roll product will be available for purchase at dispensaries in the 33 states where medical cannabis is legal.
Serious marijuana investors ought to pay attention to the complacency that’s creeping into the stock market. Historically when complacency abounds, stocks fall, unless there are new positive fundamental developments or new short-squeezes. A lot of money is to be made in marijuana.
It's a no-go for recreational marijuana in the Garden State for now. And several marijuana stocks are feeling the sting of the state's delay.
CORAL GABLES, FL / ACCESSWIRE / March 25, 2019 / The marijuana stock market has endured a whirlwind of volatility over the course of the last few years but in the first few months of 2019, companies in the cannabis sector have managed to stay strong through bearish periods of trading. It seems as though a significant portion of the changes taking place in the marijuana industry is directly connected to the recent push from the public who are insisting that lawmakers pass positive cannabis legislation. Whereas in the past cannabis was largely condemned, nowadays, consumers are well-versed in the potential health benefits of cannabis products, and the general feeling towards the cannabis sector is shifting in a positive direction.
What Drove Curaleaf’s Stock Price Last Week?Sector performance On March 22, the US market fell on concerns over global growth prospects as the yield on long-term bonds, such as the ten-year Treasury note, fell below that of short-term bonds, such
Last week, the bill that will allow the good people of New Jersey to legally buy and consume adult-use cannabis, cleared the Assembly Appropriations Committee. Investors who have been following legalization developments in New Jersey are likely encouraged by this recent move.
- There are few pure-play public market plays, but one of the hotter IPOs of 2018 was the popular Chinese device-maker Viomi Technology (VIOT). - Over 8 million water heaters are installed each year in the U.S., and with what appears to be a superior product offering, TKLS' 160% growth could just be getting started. Viomi Technology (VIOT) is a China-based maker of internet-connected home appliances, including smart refrigerators, ovens, dishwashers, robot vacuums, speakers and security devices.
Cannabis stocks were a sea of red Friday as the broader market tumbled, leaving investors to take the time to lock in recent gains.
With the market extended due to the bear trap sprung by the Fed, we were ripe for a little profit-taking. Headlines about inverted interest rates, weak German manufacturing data and the ongoing Brexit drama are providing a convenient excuse for some selling.
Curaleaf Stock Rose More than 30% on March 21(Continued from Prior Part)Fourth-quarter revenues Before we discuss analysts’ 2019 estimates, we’ll look at Curaleaf Holdings’ (CURA) (CURLF) fourth-quarter performance. The company posted its
CORAL GABLES, FL / ACCESSWIRE / March 22, 2019 / The marijuana stock market has garnered much of its notoriety due to investors focusing on the top players on the cannabis industry. Over the course of the last few months, these companies often have been the pure-play growers of the cannabis plants, as well as businesses that invest in the marijuana industry. Having said that, there is a large amount of potential within lesser-known companies in the cannabis sector, namely ancillary companies which fulfill a crucial role for the industry.